CareDx, Inc (CDNA) P/E Ratio History
UndervaluedTrading at 33.6x vs 5Y avg 175.8x · 67th percentile · Below historical baseline · Data 2014–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, CareDx, Inc (CDNA) trades at a price-to-earnings ratio of 33.6x, with a stock price of $78.56 and trailing twelve-month earnings per share of $2.34.
The current P/E is 81% below its 5-year average of 175.8x. Over the past five years, CDNA's P/E has ranged from a low of 12.2x to a high of 958.9x, placing the current valuation at the 67th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, CDNA trades at a 36% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, CDNA commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CDNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CDNA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CDNA P/E vs Peers
Reference and Genetic Labs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $32B | 36.7 | 8.67 | +171%Best | |
| $2B | 15.8Lowest | - | +165% | |
| $3B | 31.1 | 4.64Best | +14% | |
| $258B | 36.4 | 17.23 | +7% | |
| $162B | 37.6 | - | -5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CDNA Historical P/E Data (2014–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $65.00 | $2.39 | 27.2x | -85% |
| FY2026 Q2 | - | $28.50 | $2.07 | 13.8x | -92% |
| FY2025 Q3 | - | $14.54 | $1.19 | 12.2x | -93% |
| FY2025 Q2 | Jun 30 2025 | $19.54 | $1.02 | 19.2x | -89% |
| FY2025 Q1 | Mar 31 2025 | $17.75 | $1.09 | 16.3x | -91% |
| FY2024 Q4 | - | $21.41 | $0.90 | 23.8x | -86% |
| FY2015 Q1 | - | $5.54 | $0.01 | 423.3x | +141% |
| FY2014 Q4 | Dec 31 2014 | $7.25 | $0.08 | 87.2x | -50% |
| FY2014 Q3 | - | $7.00 | $0.01 | 958.9x | +446% |
Average P/E for displayed period: 175.8x
CDNA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CDNA — Frequently Asked Questions
Quick answers to the most common questions about buying CDNA stock.
What is CDNA's P/E ratio?
CareDx, Inc (CDNA) trailing twelve-month P/E ratio is 33.6x, based on TTM diluted EPS of $2.34. The 5-year average P/E is 175.8x and the historical range spans 12.2x to 958.9x.
Is CDNA stock overvalued or undervalued?
CDNA trades at 33.6x P/E, below its 5-year average of 175.8x. At the 67th percentile of its historical range (12.2x–958.9x), the stock is priced at a discount to its own history.
Is CDNA stock expensive?
No, CDNA is not expensive on a historical basis. The current P/E of 33.6x is below the 5-year average of 175.8x and sits at the 67th percentile of its valuation range.
What is CDNA's historical P/E range?
Over the past 5 years, CDNA's P/E ratio has ranged from 12.2x to 958.9x, with a median of 23.8x and an average of 175.8x. The current P/E of 33.6x places the stock at the 67th percentile of this range. Full historical data spans 2014–2026.
How does CDNA's P/E compare to the S&P 500?
CDNA trades at 33.6x P/E versus the S&P 500 median of 21.8x. The 54% premium to the market typically reflects higher expected earnings growth or quality.
How does CDNA's valuation compare to Healthcare peers?
CareDx, Inc P/E of 33.6x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CDNA's PEG ratio?
CDNA PEG ratio is N/A, based on a P/E of 33.6x and EPS growth of -143.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CDNA's earnings yield?
CDNA earnings yield is 2.98%, the inverse of its 33.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.